AlphaYou
Overview
No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.
Key stats
Aug 20- 52-wk high
- $9.42
- 52-wk low
- $5.44
- Prev close
- $7.61
- Mkt cap
- $758.1M
- Fwd P/E
- 78.1x
- Beta
- 4.82
Smart money
Earnings
Earnings came in $0.04 a share below what analysts expected.
Financials
What it sold, what it cost, what was left.
Sep 2025Dec 2025Mar 2026Jun 2026
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $30.6M | $37.2M | $22.5M | $29.1M |
| Cost of what it sold | $1.6M | $1.7M | $1.2M | $2.2M |
| Gross profit | $28.9M | $35.5M | $21.3M | $26.9M |
| What it spent | ||||
| Research and development | $2.4M | $4.8M | $6.7M | $19.1M |
| Sales and admin | $4.3M | $6.7M | $7.2M | $7.9M |
| Other operating costs | $15.3M | $23.8M | $16.7M | $14.3M |
| Total operating expenses | $22.0M | $35.3M | $30.6M | $41.3M |
| What was left | ||||
| Operating profit | $6.9M | $120.0K | -$9.4M | -$14.4M |
| Interest on debt | $1.1M | — | — | — |
| Profit before tax | $7.6M | -$66.0K | -$9.2M | -$14.4M |
| Tax | $1.7M | $1.3M | -$621.0K | -$164.0K |
| Net profit | $3.6M | -$1.7M | -$8.6M | -$10.6M |
| EBITDA | $8.3M | $629.0K | -$8.6M | -$14.4M |
Technicals
Price structure
No data yet
Technicals sync when verified market data is available. No sample data is shown.
News
What the news says
17 articles · 7 days
Coverage is mixed
Tone of tracked coverage
Gyre Therapeutics (NASDAQ:GYRE) Lowered to "Strong Sell" Rating by Zacks Research
BearishAug 20Analysts Set Expectations for GYRE Q3 Earnings
Leans bearishAug 19GYRE | Gyre Therapeutics, Inc. Common Financials - Revenue Breakdown
NeutralAug 19
